Clontech renegotiates Becton sale:
This article was originally published in Clinica
Executive Summary
Clontech Laboratories, a privately-owned US molecular biology and gene-based drug discovery company, has renegotiated its April agreement to sell to Becton Dickinson. The revised agreement has Becton paying the $200 million purchase price in cash, rather than in Becton shares as was originally agreed.